<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00566969</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA R01DA014537</org_study_id>
    <secondary_id>R01DA014537</secondary_id>
    <secondary_id>DPMC</secondary_id>
    <nct_id>NCT00566969</nct_id>
  </id_info>
  <brief_title>Cocaine Withdrawal and Pharmacotherapy Response</brief_title>
  <acronym>Carvedilol</acronym>
  <official_title>Cocaine Withdrawal and Pharmacotherapy Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A total of 120 male and female opioid dependent cocaine users will participate in this study.
      This study will be a 8-week double-blind, placebo controlled study examining the
      dose-dependent effects of carvedilol (up to 50 mg/day) in methadone stabilized patients. The
      design will have two phases: 1) a four-week &quot;treatment &quot; phase; and 2) a 4 week &quot; taper and
      detoxification or transfer&quot; phase. Subjects will be cocaine users who are on stable doses of
      methadone (60 to 140 mg/day). Carvedilol dose will be increased from 12.5mg/day to the target
      dose of either 25 or 50 mg/day as tolerated. At the end of the treatment-phase, subjects will
      undergo detoxification from methadone over a 2 to 4-week period based on an individual's
      needs, and they will concurrently be tapered off carvedilol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The adrenergic neurotransmission serves multiple functions including learning, emotional
      processing and stress response to psychological and physical challenges (Huether, 1996; Sved
      et al., 2001). Adrenergic transmission also mediates drug withdrawal states and
      stress-induced relapse to drug use (Aston-Jones et al., 2004; Stewart, 2000). Consistent with
      these preclinical findings, adrenergic blockers showed promise as a treatment of cocaine
      dependence (Kampman et al., 2001b; Kampman et al., 2006). These preliminary findings are
      significant because there are no proven pharmacotherapies for cocaine addiction although an
      estimated 2.3 million of Americans aged 12 or older are regular cocaine users (SAMHSA, 2004).
      The societal cost of cocaine addiction is estimated to be $45 billion in the US, suggesting
      that development of even modestly effective cocaine pharmacotherapies will have great
      economic benefits. For example, availability of a medication decreasing cocaine use by 10
      percent is estimated to have $745 million economic benefit in the US alone (Cartwright,
      2000). Thus, developing effective treatments for cocaine addiction is an essential goal with
      significant benefits both for the society and the individual.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Days Abstinent From Cocaine - Self Report</measure>
    <time_frame>11 weeks</time_frame>
    <description>Percent Self reported days of abstinence from any cocaine use during the 11 week trial.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Cocaine Dependence</condition>
  <condition>Opiate Dependence</condition>
  <arm_group>
    <arm_group_label>Sugar Pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>To be compared to active drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carvedilol 25 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>To be compared to placebo and Carvedilol 50 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carvedilol 50 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>To be compared to placebo and Carvedilol 25 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sugar pill</intervention_name>
    <description>Subjects randomized to placebo, carvedilol 25mg or 50mg</description>
    <arm_group_label>Sugar Pill</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol 25 mg</intervention_name>
    <description>subjects randomized to placebo, carvedilol 25mg or 50mg</description>
    <arm_group_label>Carvedilol 25 mg</arm_group_label>
    <other_name>Coreg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol 50 mg</intervention_name>
    <description>subjects randomized to placebo, carvedilol 25mg or 50mg</description>
    <arm_group_label>Carvedilol 50 mg</arm_group_label>
    <other_name>Coreg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current opioid dependence as evidenced by documented prior treatment for opioid
             dependence or signs of opiate withdrawals, self-reported history of opioid dependence
             for a consecutive 12 month period and a positive urine for opiates.

          -  Current cocaine use with self-reported use of cocaine &gt; 1 time/week in at least on
             month preceding study entry, provision of a cocaine-positive urine and fulfilled
             DSM-IV criteria for cocaine dependence

          -  For women of childbearing age, a negative pregnancy test at screening with agreement
             to use adequate contraception to prevent pregnancy and monthly pregnancy tests.

        Exclusion Criteria:

          -  current diagnosis of other drug or alcohol dependence (other than opiates, cocaine or
             tobacco);

          -  serious medical illness including asthma, diabetes, bradycardia, or other arrhythmias
             and major cardiovascular, renal, endocrine, hepatic disorders;

          -  current serious psychiatric illness or history of psychosis, schizophrenia, bipolar
             type I disorder or significant current suicidal or homicidal thoughts;

          -  screening liver function tests (AST or ALT) greater than 3 times normal;

          -  known allergy or intolerance for carvedilol or methadone.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mehmet Sofuoglu, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Veterans Hospital</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2007</study_first_submitted>
  <study_first_submitted_qc>December 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2007</study_first_posted>
  <results_first_submitted>August 16, 2016</results_first_submitted>
  <results_first_submitted_qc>August 16, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 10, 2016</results_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Mehmet Sofuoglu</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>cocaine, opiate, methadone, carvedilol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine</mesh_term>
    <mesh_term>Carvedilol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sugar Pill</title>
          <description>To be compared to active drug
sugar pill: randomly given 25mg or 50mg of a sugar pill or the active comparator</description>
        </group>
        <group group_id="P2">
          <title>Carvedilol 25 mg</title>
          <description>To be compared to sugar pill
carvedilol: randomly assigned to 25mg or 50mg of Carvedilol or sugar pill, dose determined by height and weight.</description>
        </group>
        <group group_id="P3">
          <title>Carvedilol 50 mg</title>
          <description>To be compared to sugar pill
carvedilol: randomly assigned to 25mg or 50mg of Carvedilol or sugar pill, dose determined by height and weight.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>106 subjects meeting inclusion criteria who were without exclusions and randomized to an intervention.</population>
      <group_list>
        <group group_id="B1">
          <title>Sugar Pill</title>
          <description>To be compared to active drug
sugar pill: Subjects randomized to placebo, carvedilol 25mg or 50mg</description>
        </group>
        <group group_id="B2">
          <title>Carvedilol 25 mg</title>
          <description>To be compared to placebo and Carvedilol 50 mg
carvedilol: subjects randomized to placebo, carvedilol 25mg or 50mg</description>
        </group>
        <group group_id="B3">
          <title>Carvedilol 50 mg</title>
          <description>To be compared to placebo and Carvedilol 25 mg
Carvedilol: subjects randomized to placebo, carvedilol 25mg or 50mg</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="37"/>
            <count group_id="B3" value="35"/>
            <count group_id="B4" value="106"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.6" spread="9.1"/>
                    <measurement group_id="B2" value="37.7" spread="10.9"/>
                    <measurement group_id="B3" value="39.1" spread="10.9"/>
                    <measurement group_id="B4" value="38.1" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Days Abstinent From Cocaine - Self Report</title>
        <description>Percent Self reported days of abstinence from any cocaine use during the 11 week trial.</description>
        <time_frame>11 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sugar Pill</title>
            <description>To be compared to active drug
sugar pill: randomly given 25mg or 50mg of a sugar pill or the active comparator</description>
          </group>
          <group group_id="O2">
            <title>Carvedilol 25 mg</title>
            <description>To be compared to sugar pill
carvedilol: randomly assigned to 25mg or 50mg of Carvedilol or sugar pill, dose determined by height and weight.</description>
          </group>
          <group group_id="O3">
            <title>Carvedilol 50 mg</title>
            <description>To be compared to sugar pill
carvedilol: randomly assigned to 25mg or 50mg of Carvedilol or sugar pill, dose determined by height and weight.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Days Abstinent From Cocaine - Self Report</title>
          <description>Percent Self reported days of abstinence from any cocaine use during the 11 week trial.</description>
          <units>percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.9" spread="25.3"/>
                    <measurement group_id="O2" value="72.9" spread="29"/>
                    <measurement group_id="O3" value="59.3" spread="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A hierarchical linear model was used to account for unequal variance and covariance structures across time.</non_inferiority_desc>
            <p_value>.10</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sugar Pill</title>
          <description>To be compared to active drug
sugar pill: randomly given 25mg or 50mg of a sugar pill or the active comparator</description>
        </group>
        <group group_id="E2">
          <title>Carvedilol 25 mg</title>
          <description>To be compared to sugar pill
carvedilol: randomly assigned to 25mg or 50mg of Carvedilol or sugar pill, dose determined by height and weight.</description>
        </group>
        <group group_id="E3">
          <title>Carvedilol 50 mg</title>
          <description>To be compared to sugar pill
carvedilol: randomly assigned to 25mg or 50mg of Carvedilol or sugar pill, dose determined by height and weight.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>BSI</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="19"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="28"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Decreased appetitie</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="28"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Numbness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="28"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Cramps</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="19"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="28"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Disturbed concentration</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="28"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="19"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="28"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Tiredness</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="19"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="28"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="28"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="19"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="28"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Nightmares</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="28"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="19"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="28"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="19"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="28"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mehmet Sofuoglu, M.D.,Ph.D.</name_or_title>
      <organization>Yale University</organization>
      <phone>203-932-5711 ext 4809</phone>
      <email>mehmet.sofuoglu@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

